MRTX Mirati Therapeutics Inc

Price (delayed)

$132.04

Market cap

$6.84B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$9.54

Enterprise value

$6.64B

Mirati Therapeutics is a late-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The ...

Highlights
The quick ratio is up by 43% since the previous quarter and by 10% year-on-year
MRTX's equity has soared by 97% YoY but it is down by 4% from the previous quarter
The EPS fell by 23% YoY but it rose by 4.1% QoQ
Mirati Therapeutics's net income has decreased by 47% YoY
Mirati Therapeutics's debt has increased by 2.3% from the previous quarter

Key stats

What are the main financial stats of MRTX
Market
Shares outstanding
51.82M
Market cap
$6.84B
Enterprise value
$6.64B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.29
Price to sales (P/S)
92.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
90.4
Earnings
Revenue
$73.5M
EBIT
-$479.95M
EBITDA
-$478.53M
Free cash flow
-$335.89M
Per share
EPS
-$9.54
Free cash flow per share
-$6.5
Book value per share
$21
Revenue per share
$1.42
TBVPS
$24.27
Balance sheet
Total assets
$1.25B
Total liabilities
$169.41M
Debt
$45.52M
Equity
$1.08B
Working capital
$1.05B
Liquidity
Debt to equity
0.04
Current ratio
9.6
Quick ratio
9.46
Net debt/EBITDA
0.41
Margins
EBITDA margin
-651%
Gross margin
100%
Net margin
-657.5%
Operating margin
-656.4%
Efficiency
Return on assets
-35.4%
Return on equity
-40%
Return on invested capital
-55.6%
Return on capital employed
-42.4%
Return on sales
-653%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRTX stock price

How has the Mirati Therapeutics stock price performed over time
Intraday
-3.46%
1 week
-6.49%
1 month
-19.18%
1 year
-43.66%
YTD
-39.88%
QTD
-25.36%

Financial performance

How have Mirati Therapeutics's revenue and profit performed over time
Revenue
$73.5M
Gross profit
$73.5M
Operating income
-$482.44M
Net income
-$483.25M
Gross margin
100%
Net margin
-657.5%
Mirati Therapeutics's net margin has soared by 82% from the previous quarter and by 76% YoY
The operating margin has soared by 82% QoQ and by 76% YoY
Mirati Therapeutics's net income has decreased by 47% YoY
The company's operating income fell by 43% YoY

Growth

What is Mirati Therapeutics's growth rate over time

Valuation

What is Mirati Therapeutics stock price valuation
P/E
N/A
P/B
6.29
P/S
92.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
90.4
The EPS fell by 23% YoY but it rose by 4.1% QoQ
MRTX's equity has soared by 97% YoY but it is down by 4% from the previous quarter
MRTX's price to book (P/B) is 18% lower than its last 4 quarters average of 7.7 and 4.7% lower than its 5-year quarterly average of 6.6
The price to sales (P/S) is 83% lower than the last 4 quarters average of 539.3

Efficiency

How efficient is Mirati Therapeutics business performance
The ROS has soared by 83% QoQ and by 76% YoY
Mirati Therapeutics's return on assets has increased by 35% YoY and by 13% QoQ
The company's return on equity rose by 33% YoY and by 12% QoQ
MRTX's return on invested capital is up by 29% year-on-year and by 17% since the previous quarter

Dividends

What is MRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRTX.

Financial health

How did Mirati Therapeutics financials performed over time
The total liabilities has soared by 146% YoY but it is down by 25% QoQ
The total assets has soared by 102% YoY but it has contracted by 8% from the previous quarter
Mirati Therapeutics's debt is 96% less than its equity
MRTX's equity has soared by 97% YoY but it is down by 4% from the previous quarter
Mirati Therapeutics's debt has increased by 2.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.